Business Wire · ATRA · October 14, 2026

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Get the app for more

Explore stock news, insights and company research.